JP7690470B2 - がん幹細胞を標的化するがん治療 - Google Patents
がん幹細胞を標的化するがん治療 Download PDFInfo
- Publication number
- JP7690470B2 JP7690470B2 JP2022526226A JP2022526226A JP7690470B2 JP 7690470 B2 JP7690470 B2 JP 7690470B2 JP 2022526226 A JP2022526226 A JP 2022526226A JP 2022526226 A JP2022526226 A JP 2022526226A JP 7690470 B2 JP7690470 B2 JP 7690470B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbamate
- substituted
- unsubstituted
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025089886A JP2025143254A (ja) | 2019-11-06 | 2025-05-29 | がん幹細胞を標的化するがん治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931531P | 2019-11-06 | 2019-11-06 | |
| US62/931,531 | 2019-11-06 | ||
| PCT/US2020/059329 WO2021092322A1 (en) | 2019-11-06 | 2020-11-06 | Cancer treatments targeting cancer stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025089886A Division JP2025143254A (ja) | 2019-11-06 | 2025-05-29 | がん幹細胞を標的化するがん治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553865A JP2022553865A (ja) | 2022-12-26 |
| JP2022553865A5 JP2022553865A5 (https=) | 2023-11-14 |
| JP7690470B2 true JP7690470B2 (ja) | 2025-06-10 |
Family
ID=73643356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526226A Active JP7690470B2 (ja) | 2019-11-06 | 2020-11-06 | がん幹細胞を標的化するがん治療 |
| JP2025089886A Pending JP2025143254A (ja) | 2019-11-06 | 2025-05-29 | がん幹細胞を標的化するがん治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025089886A Pending JP2025143254A (ja) | 2019-11-06 | 2025-05-29 | がん幹細胞を標的化するがん治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12612368B2 (https=) |
| EP (1) | EP4055008A1 (https=) |
| JP (2) | JP7690470B2 (https=) |
| KR (1) | KR20220110744A (https=) |
| CN (2) | CN119930509A (https=) |
| AU (1) | AU2020378067A1 (https=) |
| BR (1) | BR112022008753A2 (https=) |
| CA (1) | CA3157315A1 (https=) |
| CO (1) | CO2022007910A2 (https=) |
| IL (1) | IL292718A (https=) |
| MX (1) | MX2022005445A (https=) |
| PH (1) | PH12022551081A1 (https=) |
| WO (1) | WO2021092322A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| EP4055008A1 (en) | 2019-11-06 | 2022-09-14 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| JP2024518089A (ja) * | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
| CN119234351A (zh) | 2022-09-01 | 2024-12-31 | 株式会社Lg新能源 | 二次电池和包括该二次电池的装置 |
| CN116139141A (zh) * | 2022-12-14 | 2023-05-23 | 复旦大学 | Agk2促进肝癌的免疫治疗的用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540504A (ja) | 2007-09-28 | 2010-12-24 | サノフイ−アベンテイス | ニコチンアミド誘導体、これらの調製およびこれらの治療目的使用 |
| JP2014518223A (ja) | 2011-06-20 | 2014-07-28 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | 化合物とその治療用途 |
| JP2017516774A (ja) | 2014-05-22 | 2017-06-22 | ジェンザイム・コーポレーション | Ｎａｍｐｔ阻害剤および方法 |
| JP2019512503A (ja) | 2016-03-17 | 2019-05-16 | インダストリー−アカデミック コオペレイション ファウンデーション、ヨンセイ ユニバーシティ | ニコチンアミドホスホリボシルトランスフェラーゼ抑制用新規化合物及びこれを含む組成物 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311698A (en) | 1979-03-12 | 1982-01-19 | Haskell Theodore H | Aminoacid derivatives of cephalosporin compounds |
| US4278681A (en) | 1979-03-12 | 1981-07-14 | Warner-Lambert Co. | Antibacterial amide compounds and means for using the same |
| JPS56115784A (en) | 1980-02-15 | 1981-09-11 | Tanabe Seiyaku Co Ltd | Novel pyridinecarboxamide derivative and its preparation |
| US4315014A (en) | 1980-09-24 | 1982-02-09 | Warner-Lambert Company | Antibacterial amide compounds and pharmaceutical composition containing the same |
| US4315858A (en) | 1980-09-24 | 1982-02-16 | Warner-Lambert Company | Antibacterial amide compounds |
| JPH02127512A (ja) | 1988-11-07 | 1990-05-16 | Motoo Takayanagi | ピラジン環含有芳香族ポリアミド繊維 |
| JPH02127429A (ja) | 1988-11-07 | 1990-05-16 | Motoo Takayanagi | ピラジン環含有芳香族ポリアミドおよびその製造法 |
| GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| JP3354090B2 (ja) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| JP2000256194A (ja) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
| AU7278500A (en) | 1999-08-18 | 2001-03-13 | Aventis Cropscience Gmbh | Fungicides |
| EE200300360A (et) | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid |
| WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
| WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| WO2003055477A1 (en) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
| JP4505228B2 (ja) | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤 |
| EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| EP1738752A1 (en) | 2002-12-27 | 2007-01-03 | Schering Aktiengesellschaft | Pharmaceutical combinations comprising cis-retine acid |
| DE10334724A1 (de) | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| JP2008510726A (ja) | 2004-08-20 | 2008-04-10 | エントレメッド インコーポレイテッド | プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法 |
| ES2377430T3 (es) | 2004-09-02 | 2012-03-27 | Genentech, Inc. | Inhibidores piridílicos de la señalización de hedgehog |
| CN101128454A (zh) | 2004-12-22 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 用作抗癌药物的吡啶羧酰胺衍生物 |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| GB0500828D0 (en) | 2005-01-15 | 2005-02-23 | Astrazeneca Ab | Benzamide derivatives |
| GB0501146D0 (en) | 2005-01-20 | 2005-02-23 | Astrazeneca Ab | Novel benzamide derivatives |
| JP2008545744A (ja) | 2005-06-02 | 2008-12-18 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | フェニルアルキル置換ヘテロアリール誘導体 |
| GB0514684D0 (en) | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| BRPI0615133A2 (pt) | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| CA2630639A1 (en) | 2005-11-21 | 2007-05-31 | Tap Pharmaceutical Products, Inc. | Treatment of qt interval prolongation and diseases associated therewith |
| TWI372752B (en) | 2005-12-22 | 2012-09-21 | Nihon Nohyaku Co Ltd | Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| JP2009534458A (ja) | 2006-04-26 | 2009-09-24 | キャンサー・リサーチ・テクノロジー・リミテッド | アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用 |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| FR2904827B1 (fr) | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
| WO2008024963A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| US8324226B2 (en) | 2007-10-24 | 2012-12-04 | Cancer Research Technology Limited | Therapeutic oxy-phenyl-aryl compounds and their use |
| CA2705848C (en) | 2007-11-21 | 2016-02-02 | Bio-Rad Laboratories, Inc. | Photoluminescent metal complexes for protein staining |
| EP2639224B1 (en) | 2007-12-07 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| RU2011121655A (ru) | 2008-10-29 | 2012-12-10 | Сертрис Фармасьютикалз, Инк. | Производные пиридина, бициклические производные пиридина и родственные аналоги в качестве модуляторов сиртуина |
| US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US20130109682A1 (en) | 2010-07-06 | 2013-05-02 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
| WO2012054110A2 (en) | 2010-07-07 | 2012-04-26 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| DK2599771T3 (en) | 2010-07-30 | 2016-10-24 | Daito Chemix Corp | naphthalene |
| WO2012024179A1 (en) | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| EP2611804A1 (en) | 2010-09-03 | 2013-07-10 | Forma TM, LLC. | Novel compounds and compositions for the inhibition of nampt |
| JP5822840B2 (ja) | 2010-09-30 | 2015-11-24 | ダイトーケミックス株式会社 | 眼疾患処置薬 |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| CA2836338C (en) | 2011-05-16 | 2022-05-03 | Koninklijke Philips N.V. | Tetrazine derivatives used in bio-orthogonal drug activation |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| WO2013028445A1 (en) | 2011-08-19 | 2013-02-28 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| EP2589292A1 (en) | 2011-11-02 | 2013-05-08 | Bayer CropScience AG | Compounds with nematicidal activity |
| EP2773203A1 (en) | 2011-11-02 | 2014-09-10 | Bayer Intellectual Property GmbH | Compounds with nematicidal activity |
| GB201120993D0 (en) | 2011-12-06 | 2012-01-18 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| CA2872652A1 (en) | 2012-05-07 | 2013-11-14 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| AR091654A1 (es) | 2012-07-02 | 2015-02-18 | Biogen Idec Inc | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| FI2922574T3 (fi) | 2012-11-22 | 2023-08-11 | Tagworks Pharmaceuticals B V | Kemiallisesti pilkkoutuva ryhmä |
| US20150297741A1 (en) | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| JP5799117B2 (ja) | 2013-02-05 | 2015-10-21 | 大日本住友製薬株式会社 | ウラシル誘導体からなる医薬 |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| US20160046616A1 (en) | 2013-03-15 | 2016-02-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
| WO2014169073A1 (en) | 2013-04-09 | 2014-10-16 | Massachusetts Institute Of Technology | Drug delivery polymer and uses thereof |
| WO2014203217A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| GB201316823D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| CN105916500A (zh) | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | 用于治疗炎性疾病的化合物、药物组合物和方法 |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
| KR102265277B1 (ko) | 2014-04-11 | 2021-06-16 | 판옵테스 파르마 게스.엠.베.하. | 바이러스 억제 화합물로서의 항-염증제 |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| WO2017106436A1 (en) | 2015-12-15 | 2017-06-22 | University Of Miami | Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| CN108713013B (zh) | 2016-02-29 | 2021-06-18 | 住友化学株式会社 | 杂环化合物 |
| WO2018017589A1 (en) | 2016-07-19 | 2018-01-25 | The General Hospital Corporation | Compounds for targeting cancer stem cells |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| WO2018101424A1 (ja) | 2016-12-01 | 2018-06-07 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除組成物 |
| CN108314677B (zh) | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
| BR112019021388B1 (pt) | 2017-04-11 | 2023-10-31 | Mitsui Chemicals Crop & Life Solutions, Inc | Compostos, agente de controle de pragas agrícolas e hortícolas, fungicida agrícola e hortícola e métodos para prevenção e/ou tratamento de uma doença de plantas |
| RS65914B1 (sr) | 2017-04-18 | 2024-10-31 | Lilly Co Eli | Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja |
| JP7211358B2 (ja) | 2017-05-22 | 2023-01-24 | 小野薬品工業株式会社 | Ｅｐ４アンタゴニスト |
| EP3746070A4 (en) | 2018-01-29 | 2021-09-01 | Capulus Therapeutics, LLC | SREBP INHIBITORS WITH A 6-LINKED CENTER RING |
| US12522587B2 (en) | 2018-05-04 | 2026-01-13 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| JP7399589B2 (ja) | 2018-09-12 | 2023-12-18 | 日本化薬株式会社 | 有害生物防除剤 |
| EP4055008A1 (en) | 2019-11-06 | 2022-09-14 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| KR102210267B1 (ko) | 2020-05-26 | 2021-02-01 | (주)피엔에이치테크 | 유기발광 화합물 및 이를 포함하는 유기발광소자 |
| KR20230061442A (ko) | 2020-09-02 | 2023-05-08 | 도꾜 다이가꾸 | 유기 반도체 재료 |
| JP2024518089A (ja) | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
-
2020
- 2020-11-06 EP EP20816347.7A patent/EP4055008A1/en active Pending
- 2020-11-06 CN CN202510009927.XA patent/CN119930509A/zh active Pending
- 2020-11-06 CA CA3157315A patent/CA3157315A1/en active Pending
- 2020-11-06 BR BR112022008753A patent/BR112022008753A2/pt unknown
- 2020-11-06 MX MX2022005445A patent/MX2022005445A/es unknown
- 2020-11-06 CN CN202080091217.1A patent/CN114929672B/zh active Active
- 2020-11-06 PH PH1/2022/551081A patent/PH12022551081A1/en unknown
- 2020-11-06 JP JP2022526226A patent/JP7690470B2/ja active Active
- 2020-11-06 KR KR1020227018395A patent/KR20220110744A/ko active Pending
- 2020-11-06 US US17/774,583 patent/US12612368B2/en active Active
- 2020-11-06 AU AU2020378067A patent/AU2020378067A1/en active Pending
- 2020-11-06 WO PCT/US2020/059329 patent/WO2021092322A1/en not_active Ceased
-
2022
- 2022-05-03 IL IL292718A patent/IL292718A/en unknown
- 2022-06-03 CO CONC2022/0007910A patent/CO2022007910A2/es unknown
-
2025
- 2025-05-29 JP JP2025089886A patent/JP2025143254A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540504A (ja) | 2007-09-28 | 2010-12-24 | サノフイ−アベンテイス | ニコチンアミド誘導体、これらの調製およびこれらの治療目的使用 |
| JP2014518223A (ja) | 2011-06-20 | 2014-07-28 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | 化合物とその治療用途 |
| JP2017516774A (ja) | 2014-05-22 | 2017-06-22 | ジェンザイム・コーポレーション | Ｎａｍｐｔ阻害剤および方法 |
| JP2019512503A (ja) | 2016-03-17 | 2019-05-16 | インダストリー−アカデミック コオペレイション ファウンデーション、ヨンセイ ユニバーシティ | ニコチンアミドホスホリボシルトランスフェラーゼ抑制用新規化合物及びこれを含む組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022553865A (ja) | 2022-12-26 |
| CN119930509A (zh) | 2025-05-06 |
| AU2020378067A1 (en) | 2022-05-26 |
| CA3157315A1 (en) | 2021-05-14 |
| EP4055008A1 (en) | 2022-09-14 |
| WO2021092322A1 (en) | 2021-05-14 |
| BR112022008753A2 (pt) | 2022-07-19 |
| PH12022551081A1 (en) | 2024-06-19 |
| KR20220110744A (ko) | 2022-08-09 |
| IL292718A (en) | 2022-07-01 |
| JP2025143254A (ja) | 2025-10-01 |
| CN114929672A (zh) | 2022-08-19 |
| CO2022007910A2 (es) | 2022-08-19 |
| CN114929672B (zh) | 2025-01-21 |
| MX2022005445A (es) | 2022-08-10 |
| US20230023124A1 (en) | 2023-01-26 |
| US12612368B2 (en) | 2026-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690470B2 (ja) | がん幹細胞を標的化するがん治療 | |
| AU2017363307B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| JP7643874B2 (ja) | がん幹細胞を標的化するがん治療 | |
| JP7308146B2 (ja) | インターロイキン１受容体関連キナーゼの阻害剤およびその使用 | |
| JP7590185B2 (ja) | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 | |
| JP7675070B2 (ja) | 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体 | |
| EP3876939A1 (en) | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| JP2024518089A (ja) | Ｎａｍｐｔ阻害剤とその使用 | |
| JP2020529998A (ja) | 血漿カリクレインの阻害剤およびその使用 | |
| CN120659777A (zh) | 募集Cereblon的Bcl-xL/Bcl-2双重降解剂 | |
| JP2024529487A (ja) | Ｒｏｃｋ２阻害剤およびその使用 | |
| HK40120024A (zh) | 靶向癌症干细胞的癌症治疗 | |
| US20260125367A1 (en) | Cancer treatments targeting cancer stem cells | |
| AU2020362194B2 (en) | A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases | |
| WO2023196714A9 (en) | Inhibitors of ddr1 and ddr2 for the treatment of arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240917 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240919 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241217 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20241217 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250428 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250529 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7690470 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |